Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.

[PR Newswire] – With MST-188 in an ongoing pivotal trial for sickle cell disease and a phase 2 trial expected to initiate this quarter in acute limb ischemia, the addition of another phase 2-ready asset further enhances our pipeline, providing us with di more

View todays social media effects on MSTX

View the latest stocks trending across Twitter. Click to view dashboard

See who Mast is hiring next, click here to view